Literature DB >> 21821298

Questionnaire-based survey on the clinical management of canine leishmaniosis in the Madrid region (central Spain).

R Gálvez1, G Miró, M A Descalzo, R Molina.   

Abstract

This paper describes a questionnaire designed to gain information on how veterinarians clinically manage canine leishmaniosis (CanL) in the Madrid region (central Spain). The present survey is one of the several similar questionnaire-based surveys conducted within the framework of the project EDEN (Emerging Diseases in a changing European eNvironment). The questionnaire sought to obtain data regarding the main clinical manifestations observed, the diagnostic methods used and the preventive measures recommended. Its Spanish version was sent by post to veterinary practitioners within the study area in two lots, one sent out in December 2006 and the other in March 2007. Only 174 of the 760 questionnaires sent were completed and returned (reply rate of 23%). Among the completed questionnaires, clinics differed widely in terms of features such as the habitats of the dogs (urban, peri-urban or rural) and patient volumes. Clinics attending dogs from peri-urban/rural habitats reported more suspected (p<0.001), confirmed (p=0.001) and newly diagnosed (p=0.001) cases/year than clinics providing service to a city clientele alone. According to the veterinary practitioners, skin lesions, lymphadenomegaly and weight loss were commonly observed, although these signs are not specific to CanL. Signs described to be of high diagnostic value were epistaxis and kidney disease. All the veterinarians polled reported that a suspicion of Leishmania infantum infection was confirmed by at least a serological method; the immunofluorescence antibody test (IFAT) being the technique most used. To prevent the disease, most vets recommended topical synthetic pyrethroids applied as impregnated collars or spot-ons. It is observed that despite considerable progress is being made in clinical management and controlling the disease, in Madrid Region its incidence continues to increase.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821298     DOI: 10.1016/j.prevetmed.2011.07.002

Source DB:  PubMed          Journal:  Prev Vet Med        ISSN: 0167-5877            Impact factor:   2.670


  5 in total

1.  Management of canine leishmaniosis in endemic SW European regions: a questionnaire-based multinational survey.

Authors:  Patrick Bourdeau; Manolis N Saridomichelakis; Ana Oliveira; Gaetano Oliva; Tina Kotnik; Rosa Gálvez; Valentina Foglia Manzillo; Alex F Koutinas; Isabel Pereira da Fonseca; Guadalupe Miró
Journal:  Parasit Vectors       Date:  2014-03-24       Impact factor: 3.876

2.  Latest trends in L. infantum infection in dogs in Spain, Part II: current clinical management and control according to a national survey of veterinary practitioners.

Authors:  Ana Montoya; Rosa Gálvez; Rocío Checa; Juliana Sarquis; Alexandra Plaza; Juan Pedro Barrera; Valentina Marino; Guadalupe Miró
Journal:  Parasit Vectors       Date:  2020-04-21       Impact factor: 3.876

3.  Questionnaire-based survey on distribution and clinical incidence of canine babesiosis in France.

Authors:  Lénaïg Halos; Isabelle Lebert; Isabelle Chao; Gwenaël Vourc'h; Christian Ducrot; David Abrial; Jean-François Ravier; Jacques Guillot
Journal:  BMC Vet Res       Date:  2013-02-28       Impact factor: 2.741

4.  Seropositivity rates for agents of canine vector-borne diseases in Spain: a multicentre study.

Authors:  Guadalupe Miró; Ana Montoya; Xavier Roura; Rosa Gálvez; Angel Sainz
Journal:  Parasit Vectors       Date:  2013-04-22       Impact factor: 3.876

5.  A Questionnaire-Based Survey on the Long-Term Management of Canine Leishmaniosis by Veterinary Practitioners.

Authors:  Maria A Pereira; Rute Santos; Carmen Nóbrega; Cristina Mega; Rita Cruz; Fernando Esteves; Carla Santos; Catarina Coelho; João R Mesquita; Helena Vala; Gabriela Santos-Gomes
Journal:  Animals (Basel)       Date:  2022-03-14       Impact factor: 2.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.